Evidence map›Paper›PMID 37914412›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

HSP90, a Common Therapeutic Target for Suppressing Skin Injury Caused by Exposure to Chemically Diverse Classes of Blistering Agents.

Ritesh Kumar Srivastava, Suhail Muzaffar, Jasim Khan, David K Crossman, Anupam Agarwal, Mohammad Athar

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ritesh Kumar SrivastavaUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama riteshsrivastava@uabmc.edu.
Suhail MuzaffarUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Jasim KhanUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama.
David K CrossmanUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Anupam AgarwalUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Mohammad AtharUAB Research Center of Excellence in Arsenicals, Departments of Dermatology (R.K.S., S.M., J.K., M.A.) and Genetics (D.K.C.) and Division of Nephrology, Department of Medicine (A.A.), University of Alabama at Birmingham, Birmingham, Alabama.
University of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
UAB Research Center of Excellence in ArsenicalsU54ES030246 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2018 to 2022
$19.0M
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin InjuryU01AR078544 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2020 to 2024
$3.9M
NCI NIH HHS P30 CA013148NIAMS NIH HHS U01 AR078544NIEHS NIH HHS U54 ES030246
6 · The paper itself

Abstract

Vesicants such as arsenicals and mustards produce highly painful cutaneous inflammatory and blistering responses, hence developed as chemical weapons during World War I/II. Here, using lewisite and sulfur mustard surrogates, namely phenylarsine oxide (PAO) and 2-chloroethyl ethyl sulfide (CEES), respectively, we defined a common underlying mechanism of toxic action by these two distinct classes of vesicants. Murine skin exposure to these chemicals causes tissue destruction characterized by increase in skin bifold thickness, Draize score, infiltration of inflammatory cells, and apoptosis of epidermal and dermal cells. RNA sequencing analysis identified ∼346 inflammatory genes that were commonly altered by both PAO and CEES, along with the identification of cytokine signaling activation as the top canonical pathway. Activation of several proinflammatory genes and pathways is associated with phosphorylation-dependent activation of heat shock protein 90

Indexed as

ArsenicalsChemical Warfare AgentsMustard GasAnimalsHumansIrritantsMiceNLR Family, Pyrin Domain-Containing 3 ProteinSkin2-chloroethyl ethyl sulfideArsenicalsChemical Warfare AgentsIrritantsMustard GasNLR Family, Pyrin Domain-Containing 3 Protein

Identifiers

PMID37914412
PMCPMC10801768
OpenAlexW4388124184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.